Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study

ConclusionThis phase II trial using pemetrexed/erlotinib in metastatic CRC with high EGFR expression met the primary endpoint of tumor response.Trial RegistrationThis study was registered at ClinicalTrials.gov (number NCT03086538).
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research